Sanofi (SNY)

So what's the narrative? Simple: the recession is ending, it turned out to be a V recession and recovery after all.

The return of NYSE floor traders is symbolic of the return to normalcy, as vaccine candidate manufacturers are scaling up for mass production.

I'm long this name, as I am several of the others involved. Will I add on a day like this?

Jerome Powell hit the airwaves with some words of caution and comfort. Nvidia is running into earnings.

Trump administration taps former GlaxoSmithKline exec as head of vaccine task force, and how I'm playing Walmart and Datadog.

Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.

It's imperative that people get back to work, so we have this great compromise -- let's see how it might play out.

More government funding is approved to fight Covid-19 layoffs, Gilead sells off on early reports around China trials and Intel announces earnings.

The drugmaker that is partnering with Sanofi to develop a vaccine has seen its shares push higher after declining to a low in late March.

There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.

The drug and vaccine maker possibly could see its shares double according to a key chart.

Fujifilm Holdings has a promising drug that seems to work in improving the outcome for coronavirus patients in China and Japan, though Avigan is a treatment not a cure.

I am pretty well covered in my 'virus group'. I could definitely see bringing a few shares of REGN on board the next time the algorithms include that name in a broad selloff. Not before.

The race is on. The prize could be countless lives saved and perhaps billions of dollars in revenue.

The Medical Technology Stock Letter's top pick rose 357% in 2019.

TG Therapeutics and Exelixis could find themselves on the shopping lists of other companies.

The real threat here would be if the Fed were fooled by domestic economic data that remains better than bad, from properly preparing for a very uncertain future.

A big jump in the market cap of Google's parent is in store thanks to an impressive second-quarter report.

The initial public offering of Hansoh Pharmaceutical Group made the Chinese couple Zhong Huijuan and Sun Piaoyang the richest in the nation.

Chinese authorities are auditing the books of 77 drugmakers, including three multinationals, they say were selected at random. Were they motivated by embarrassment over a college-admissions payment made by a Chinese pharmaceuticals' tycoon?

For investors interested in biotech, there's a lot to choose from, with options ranging from startups with potentially blockbuster new treatments to companies those that have been around the block a few times.

One of pharma's biggest CEO's talks M&A action on the exchange.

Do we have to run for the hills? Not necessarily.

Markets closed near session highs Monday.

The charges were related to an interest-rate problem.

As the Trump administration reportedly considers government controlled 5G, investors prepare for a hectic week of earnings.

Consumer spending should be more than solid given wage increases.

Another New England Patriots win in the Super Bowl could mean bad things for the stock market. What government shutdown?